Medindia
Medindia LOGIN REGISTER
Advertisement

Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results

Thursday, October 23, 2008 General News
Advertisement
SAN DIEGO, Oct. 22 Neurocrine Biosciences, Inc.(Nasdaq: NBIX) announced today that the Company will report its third quarter2008 financial results after the Nasdaq market closes on Tuesday, October 28,2008. Neurocrine will host a live conference call and webcast to discuss itsfinancial results and provide a Company update Tuesday afternoon, October 28,2008 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Advertisement

Participants can access the live conference call by dialing 1-800-894-5910(US) or 785-424-1052 (International) using the conference ID: 7NBIX2. The callcan also be accessed via the webcast through the Company's website athttp://www.neurocrine.com
Advertisement

If you are unable to attend the Webcast and would like further informationon this announcement please contact the Investor Relations Department atNeurocrine Biosciences at (858) 617-7600. A replay of the Conference Call willbe available approximately one hour after the conclusion of the call bydialing 1-800-723-5154 (US) or 402-220-2661 (International) using theconference ID: 7NBIX2. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical companyfocused on neurological and endocrine diseases and disorders. The productcandidates address some of the largest pharmaceutical markets in the worldincluding endometriosis, irritable bowel syndrome, anxiety, depression, pain,diabetes, insomnia, and other neurological and endocrine related diseases anddisorders. Neurocrine Biosciences, Inc. news releases are available throughthe Company's website via the Internet at http://www.neurocrine.com

SOURCE Neurocrine Biosciences, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close